Data as of May 22
| +0.01 / +0.40%|
Dyax Corp. is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel biotherapeutics for unmet medical needs. It has two business elements which include Angioedema Franchise and Phage Display Licensing and Funded Research Program. The company's product, KALBITOR (ecallantide) has been approved under the brand name KALBITOR in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients who are 16 years of age and older. It has established partnerships worldwide to develop and commercialize ecallantide for the treatment of HAE in key regions including Japan, Europe, North Africa, the Middle East, Russia and Israel. The company is also exploring other potential indications for ecallantide, either alone or through partnerships, including drug-induced angioedema and retinal vein occlusion-induced macular edema. Ecallantide and other compounds in Dyax's pipeline were identified using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. As part of its Licensing and Funded Research Program, Dyax leverages this technology broadly revenue generating licenses and collaborations for therapeutic discovery, as well as for affinity separations, diagnostic imaging, and research reagents. Dyax was founded in 1989 by Henry E. Blair and is headquartered in Burlington, MA.
|Henry E. Blair||Chairman|
|Gustav A. Christensen, MBA||President, Chief Executive Officer & Director|
|George V. Migausky, MBA||Chief Financial Officer & Executive Vice President|
|Burt A. Adelman, MD||Chief Medical Officer, EVP-Research & Development|
|Andrew D. Ashe||Senior VP-Administration & General Counsel|